DKP105

DKP105 is an improved new drug (incrementally modified drug) being developed by Dongkwang for the treatment of hyperlipidemia. It is a small molecule therapeutic currently in the preclinical or early development stage. As an 'improved new drug' (개량신약) in the South Korean regulatory context, it likely represents a new formulation, salt, or combination of existing lipid-lowering agents designed to provide clinical advantages such as enhanced efficacy, improved safety profiles, or better patient compliance. The specific molecular target and active ingredients have not been publicly disclosed by the developer, although the program is categorized within their R&D history as a small molecule lipid-modulating therapy.